Certified by Founder
Lodge
Brixton Biosciences
start up
United States
- Cambridge, MA
- 15/05/2024
- Series B
- $33,000,000
Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for chronic and acute pain.
- Industry Biotechnology Research
- Website https://www.brixtonbio.com/
- LinkedIn https://www.linkedin.com/company/brixtonbiosciences/
Project Eleven | $20,000,000 | (Jan 16, 2026)
CYB3R OPERATIONS | $5,400,000 | (Jan 16, 2026)
Quadric | $30,000,000 | (Jan 16, 2026)
GovDash | $30,000,000 | (Jan 16, 2026)
RouteSense | $2,000,000 | (Jan 16, 2026)
Vista AI | $29,500,000 | (Jan 16, 2026)
depthfirst | $40,000,000 | (Jan 16, 2026)
FOVC | $2,000,000 | (Jan 16, 2026)
VoiceRun | $5,500,000 | (Jan 16, 2026)
Emversity | $30,000,000 | (Jan 16, 2026)
Ammobia | $7,500,000 | (Jan 16, 2026)
Pinch AI | $5,000,000 | (Jan 16, 2026)